AliveCor

Last updated
AliveCor, Inc.
Company type Private
Industry Medical Devices, Artificial Intelligence
Founded2011 [1]
FoundersDavid Albert, Bruce Satchwell, Kim Barnett
Headquarters Mountain View, California
Key people
Priya Abani, CEO
David Albert, Chief Medical Officer [2]
Number of employees
150 [3]
Website alivecor.com

AliveCor is a medical device and AI company that develops ECG hardware and software compatible with consumer mobile devices to enable remote heart rhythm monitoring and detection of abnormal heart rhythms, or arrhythmias. [4] [5] AliveCor was founded in 2011 and is headquartered in Mountain View, California, the United States.

Contents

History

The company was co-founded in 2011 by David Albert, a medical doctor and former chief clinical scientist of cardiology at General Electric, along with scientists Bruce Satchwell and Kim Barnett. [6] [7] Albert began working on ECGs for handheld computers in 1990, when the first palm top computer was released by Hewlett-Packard. [8] Their work led to a 1998 patent for wireless transmission of ECGs in handheld devices. [8] [9]

In December 2010, Albert demonstrated a prototype of an iPhone ECG through a YouTube video. [6] After the video received attention from the media, Albert was approached by venture capitalists and industry partners to fund the new company. [8] AliveCor received its first $3 million in financing in 2011. [6]

In 2011, AliveCor finalized the design of the AliveCor iPhone ECG, a single-lead ECG device that attaches to either the iPhone 4 or iPhone 4S as a phone case. This device gained FDA approval in 2012, and it was available for sale only to doctors for $200. [10] To secure the FDA-clearance, AliveCor ran a clinical trial to test both the device hardware and the associated iPhone app. The study investigated how the single-lead ECG compared to a traditional 12-lead device. [11] A second study looked at whether 54 participants with no medical training could determine how to use the phone case to record ECG's on themselves and others. [12] The latter study revealed two subjects with serious heart conditions. [10] [12] [13] This iPhone case ECG was not approved for over-the-counter (OTC) sales as of December 2012, although AliveCor was seeking such approval from the FDA. The AliveCor iPhone ECG case does not fit on the iPhone 5 due to the change in geometry of the phone, and it would need further FDA approval to be used with the iPhone 5. [10]

In October of 2013, AliveCor announced a new ECG device that would, for the first time, support Android devices. This new device would no longer need to fit the smartphone perfectly, because it was not a smartphone case. Rather, it was a flat rectangle slightly larger than a stick of gum. [14] This device was eventually marketed as the first-generation Kardia Mobile. It was sold directly to patients.

The KardiaMobile single-lead device requires placing one fingertip from each hand on its two electrodes (metal sensor pads) for 30 seconds, allowing the device to collect a medical-grade ECG reading. [15] The resulting single-lead ECG recording is equivalent to lead I from a 12-lead ECG. [16] In a randomized controlled trial conducted in the UK, patients given an AliveCor EKG device to use at home were significantly more likely than control group patients to receive a timely and correct diagnosis of atrial fibrillation (AF). The 500 treatment-group patients recorded 60,440 EKGs at home throughout the study, and 76% of these were interpreted as "normal" (not AF) by the Kardia app's automated algorithm. None of these readings were found to show AF when reviewed by cardiologists, representing a 0% false negative rate. However, the false positive rate was 95%, meaning that the automated software often reported atrial fibrillation in cases where the cardiologist concluded there was no AF. [16] The recording can be analyzed in a rudimentary fashion within the iPhone app, and it can be saved locally on the phone. Additional services are available for additional fees: the data can be sent to AliveCor for storage in the cloud, it can be transmitted to the patient's own physician, or it can be interpreted professionally by a cardiologist who is board certified in the United States, or in certain other countries. As of March 2017, the Kardia Mobile device sells for $100. [15]

While its first-generation ECG devices relied on medical professionals to analyze readings, in 2015, the company received FDA clearance to have the device itself instantly notify the user if certain heart rhythm abnormalities were detected. [17]

The company appointed former Google and Microsoft executive Vic Gundotra as its CEO in November 2015. [18]

In 2017, the company introduced software that used a neural network to build a profile of the user's ECG patterns over the course of about a month. Then later, if something changes, the device can alert the patient's doctor of a potential abnormality even if couldn't make a specific diagnosis. [5]

By the end of 2017, the FDA had cleared the KardiaBand ECG reader as a medical device accessory to the Apple Watch. [19] The KardiaBand had been approved for use in Europe earlier in the year. [19] A study by the Cleveland Clinic showed the KardiaBand could distinguish between atrial fibrillation and a normal heart rhythm with 93 percent sensitivity and 94 percent specificity; sensitivity increased to 99 percent with physician review of the reading. [20]

After Gunotra departed in February 2018, Ira Bahr was appointed as interim CEO. [21]

In 2019, the company ended sales of the KardiaBand ECG reader. [22]

Priya Abani joined AliveCor as CEO in 2019. Before joining the company, Abani served as general manager and director of Alexa voice services. [23]

Lawsuits involving Apple

In December 2020, AliveCor sued Apple, alleging that Apple Watch Series 4, 5, and 6 infringed three of its patents by copying technologies used in the KardiaBand ECG reader. Then in April 2021, AliveCor filed a complaint with the U.S. International Trade Commission (ITC), alleging infringement of the same three patents, and asked the ITC to block Apple from importing Apple Watches manufactured overseas. The following month, AliveCor filed a federal antitrust lawsuit against Apple, claiming Apple sought to monopolize the heartrate analysis market by changing the watch's operating system to be incompatible with rival technologies. [24] [25]

On December 2, 2022, Apple sued AliveCor, claiming AliveCor copied technologies Apple had developed in 2008, two years before AliveCor was founded, and therefore its patent rights had been violated. [26] On December 6, the U.S. Patent and Trademark Office (USPTO) invalidated the three AliveCor patents in response to an earlier request by Apple. [27] On December 22, the ITC ruled that Apple Watch infringed two of the three patents, and that their import should be banned. The Biden administration was given 60 days to decide whether to veto the ruling, and a $2.00 per unit bond for was set for watches imported or sold during the review period. However, the ITC suspended enforcement of both the import ban and bond assessment pending the outcome of appeals challenging the USPTO decision. [28] [29] President Biden upheld the ITC ruling in February 2023 – the first ITC ruling against Apple to clear presidential review. It was estimated that court appeals pursued by both companies could delay any orders taking effect for up to 18 months. [30]

In June 2023, a U.S. district court judge ruled against AliveCor in its 2021 antitrust lawsuit against Apple, but AliveCor's unfair competition claim against Apple is ongoing as of September 2023. [31] Both parties were scheduled to return to court in October 2023 for dispositive motions. [31] In February 2024, the federal judge ruled in Apple’s favor and dismissed the antitrust lawsuit. [32] AliveCor said it plans to appeal the ruling. [33]

Products

KardiaMobile KardiaMobile.jpg
KardiaMobile

Financing

In 2017, AliveCor raised $30 million in series D funding from medical-device maker Omron and the Mayo Clinic, bringing the total raised to date to $43.5 million. [43]

In 2020, the company raised $65 million in series E funding, led by Omron with Khosla Ventures, WP Global Partners, Qualcomm Ventures and Bold Capital Partners. [44]

In 2022, the company announced that it had completed a Series F financing round for an undisclosed amount, led by GE Healthcare with participation from Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, WP Global Partners and Pegasus Tech Ventures. [45]

See also

Related Research Articles

<span class="mw-page-title-main">Electrocardiography</span> Examination of the hearts electrical activity

Electrocardiography is the process of producing an electrocardiogram, a recording of the heart's electrical activity through repeated cardiac cycles. It is an electrogram of the heart which is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin. These electrodes detect the small electrical changes that are a consequence of cardiac muscle depolarization followed by repolarization during each cardiac cycle (heartbeat). Changes in the normal ECG pattern occur in numerous cardiac abnormalities, including:

<span class="mw-page-title-main">Palpitations</span> Perceived cardiac abnormality in which ones heartbeat can be felt

Palpitations are perceived abnormalities of the heartbeat characterized by awareness of cardiac muscle contractions in the chest, which is further characterized by the hard, fast and/or irregular beatings of the heart.

<span class="mw-page-title-main">Rivaroxaban</span> Anticoagulant drug

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

<span class="mw-page-title-main">Dabigatran</span> Anticoagulant medication

Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. In a meta analysis of 7 different studies, there was no benefit of dabigatran over warfarin in preventing ischemic stroke; however, dabigatran were associated with a lower hazard for intracranial bleeding compared with warfarin, but also had a higher risk of gastrointestinal bleeding relative to warfarin. It is taken by mouth.

<span class="mw-page-title-main">Dronedarone</span> Medication

Dronedarone, sold under the brand name Multaq, is a class III antiarrhythmic medication developed by Sanofi-Aventis. It was approved by the US Food and Drug Administration (FDA) in July 2009. Besides being indicated in arrhythmias, it was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. The FDA label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in people with moderate to severe congestive heart failure.

<span class="mw-page-title-main">Masimo</span> American health technology company

Masimo Corporation is a health technology and consumer electronics company based in Irvine, California. The company primarily manufactures patient monitoring devices and technologies, including non-invasive sensors using optical technology, patient management, and telehealth platforms. In 2022, the company expanded into home audio by acquiring Sound United, and began to manufacture health-oriented wearable devices.

<span class="mw-page-title-main">Atrial fibrillation</span> Irregular beating of the atria of the heart

Atrial fibrillation is an abnormal heart rhythm (arrhythmia) characterized by rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF.

A wearable cardioverter defibrillator (WCD) is a non-invasive, external device for patients at risk of sudden cardiac arrest (SCA). It allows physicians time to assess their patient's arrhythmic risk and see if their ejection fraction improves before determining the next steps in patient care. It is a leased device. A summary of the device, its technology and indications was published in 2017 and reviewed by the EHRA Scientific Documents Committee.

Withings is a French consumer electronics company headquartered in Issy-les-Moulineaux, France. It also has offices in Boston, Massachusetts, USA, and Hong Kong, and distributes its products worldwide. Withings is known for design and innovation in connected devices, such as the first Wi-Fi scale on the market, an FDA-cleared blood pressure monitor, a smart sleep system, and a line of automatic activity tracking watches. It also provides B2B services for healthcare providers and researchers.

<span class="mw-page-title-main">Smartwatch</span> Wearable computer in the form of a watch

A smartwatch is a portable and wearable computer device in a form of a watch; modern smartwatches provide a local touchscreen interface for daily use, while an associated smartphone app provides management and telemetry, such as long-term biomonitoring. While early models could perform basic tasks such as calculations, digital time telling, translations, and game-playing, smartwatches released since 2015 have more general functionality closer to smartphones, including mobile apps, a mobile operating system, and WiFi/Bluetooth connectivity. Some smartwatches function as portable media players, with FM radio and playback of digital audio and video files via a Bluetooth headset. Some models, called watch phones, have mobile cellular functionality such as making telephone calls.

<span class="mw-page-title-main">Apixaban</span> Anticoagulant medication

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

The smartphone wars or smartphone patents licensing and litigation refers to commercial struggles among smartphone manufacturers including Sony Mobile, Google, Apple Inc., Samsung, Microsoft, Nokia, Motorola, Huawei, LG Electronics, ZTE and HTC, by patent litigation and other means. The conflict is part of the wider "patent wars" between technology and software corporations.

Preventice, Inc., formerly known as Boost Information Systems, Inc., was founded in 2007 by Jonathan Otterstatter, Scott Burrichter, Greg Wobig, and Dan Spors. The company is headquartered in Rochester, Minnesota.

<span class="mw-page-title-main">Implantable loop recorder</span>

An implantable loop recorder (ILR), also known as an insertable cardiac monitor (ICM), is a small device that is implanted under the skin of the chest for cardiac monitoring, to record the heart's electrical activity for an extended period.

<span class="mw-page-title-main">Activity tracker</span> Device or application for monitoring fitness

An activity tracker involves the practice of measuring and collecting data on an individual's physical and psychological activity to keep track and maintain documentation regarding their health and wellness. Used for many groups even animals as seen in collar-mounted activity trackers for dogs. A lot of the data is collected through wearable technology such as wristbands which sync with mobile apps through Apple and Samsung. As daily technologies such as phones and computers have been innovated, it paved the way for such wearable tracking technologies to be advanced. There are a variety of stakeholders involved in the usage of activity tracking through wearable technology and mobile health apps, knowing how much they track ranging from fitness, mood, sleep, water intake, medicine usage, sexual activity, menstruation, and potential diseases raises the concern on privacy given a lot of data is collected and analyzed. Through many studies that have been reviewed, data on the various demographics and goals these technologies are used provide more insight into their purposes.

Wireless ambulatory electrocardiography (ECG) is a type of ambulatory electrocardiography with recording devices that use wireless technology, such as Bluetooth and smartphones, for at-home cardiac monitoring (monitoring of heart rhythms). These devices are generally recommended to people who have been previously diagnosed with arrhythmias and want to have them monitored, or for those who have suspected arrhythmias and need to be monitored over an extended period of time in order to be diagnosed.

AFIB Technology is a feature in sphygmomanometer devices that is designed to detect and monitor the incidence of atrial fibrillation in patients. The technology was designed, patented, and is currently used by the Microlife Corporation. It has been the subject of numerous medical studies and has been validated for in-home and clinical use. It can be found in several Microlife devices, including the WatchBP Home A, BP A200 Plus, WatchBP Office, and WatchBP O3.

Qardio, Inc. is an American technology company that specializes in heart health monitoring products. It was founded by Marco Peluso and Rosario Iannella in early 2012.

<span class="mw-page-title-main">CardiacSense Ltd</span> Israeli medical products company

CardiacSense is a developer of a wearable technology for continuous cardiac arrhythmia detection and vital signs monitoring. CardiacSense is based in Caesarea, Israel.

Health Innovation Manchester is an academic health science centre established in October 2017 to drive innovation in healthcare in Greater Manchester. It is closely associated with the Greater Manchester Health and Social Care Partnership.

References

  1. ↑ Gibbs, Colin (August 3, 2017). "Fierce 15: AliveCor". Fierce Wireless. Retrieved July 27, 2021.
  2. ↑ Bruining, Nico (March 3, 2023). "Meet key digital health thought leaders: David Albert". European Heart Journal - Digital Health. 4 (3). Oxford University Press (OUP): 139–140. doi: 10.1093/ehjdh/ztad020 . ISSN   2634-3916.
  3. ↑ Evers-Hillstrom, Karl (February 17, 2023). "Apple Watch ban: Biden will make decision next week". The Hill. Retrieved August 16, 2023.
  4. ↑ "AliveCor: Most Innovative Company | Fast Company". Fast Company. Retrieved July 27, 2021.
  5. 1 2 "Ex-Googlers Build a Neural Network to Protect Your Heart". WIRED. March 20, 2017. Retrieved July 27, 2021.
  6. 1 2 3 Doln, Brian (August 2, 2011). "iPhone ECG developer AliveCor raises $3 million". MobiHealthNews. Retrieved July 27, 2021.
  7. ↑ Landi, Heather (April 22, 2021). "AliveCor seeks to bar U.S. sales of Apple Watch alleging ECG patent infringement". Fierce Healthcare. Retrieved July 18, 2023.
  8. 1 2 3 "Ahead of His Time". MDDI Online. January 3, 2012. Retrieved July 27, 2021.
  9. ↑ "Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals". Justia. June 4, 1996. Retrieved July 18, 2023.
  10. 1 2 3 "Mark Wilson" (2012-05-12). "This $200 iPhone Case Is An FDA-Approved EKG Machine". CO.DESIGN . Fast Company. Archived from the original on 2018-04-18. Retrieved March 29, 2018.
  11. ↑ Garabelli, Paul; Albert, David (11 May 2012). "Innovation Abstract # 12-IA-9662-HRS". Heart Rhythm Society's 33rd Annual Scientific Sessions.
  12. 1 2 Gaglani, Shiv (March 30, 2012). "AliveCor Takes Heart in Initial Findings of iPhone ECG Study". Medgadget. Retrieved July 18, 2023.
  13. ↑ Empson, Rip (4 December 2012). "Mobile Health Moves Forward: FDA Approves AliveCor's Heart Monitor For The iPhone". TechCrunch . Retrieved July 27, 2021.
  14. ↑ AliveCor (2013-10-04). "AliveCor Unveils Versatile Heart Monitor - Technology can now be used with both iOS and Android smartphones". AliveCor Newsroom. Retrieved 19 April 2024.
  15. 1 2 3 Magistretti, Bérénice (March 16, 2017). "AliveCor raises $30 million for its credit card-sized heart monitor and app". VentureBeat. Retrieved July 27, 2021.
  16. 1 2 Halcox, Julian PJ; Wareham, Kathie; Gilmore, Mark (2017-11-07). "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study". Circulation (136): 1784–1794. doi: 10.1161/CIRCULATIONAHA.117.030583 . PMID   28851729 . Retrieved 19 April 2024.
  17. ↑ "FDA clears AliveCor's automated detectors that record and display ECG rhythm". Medical Life Sciences News. January 29, 2015. Retrieved July 27, 2021.
  18. ↑ Fried, Ina (March 16, 2016). "Interview with Former Google Executive and AliveCor CEO Vic Gundotra". Medgadget. Retrieved August 10, 2023.
  19. 1 2 Buhr, Sarah (November 30, 2017). "FDA clears AliveCor's Kardiaband as the first medical device accessory for the Apple Watch – TechCrunch". techcrunch.com. Retrieved July 27, 2021.
  20. ↑ Clover, Juli (March 11, 2018). "Study Suggests AliveCor KardiaBand for Apple Watch Can Be Used With AI Algorithm to Detect High Potassium" . Retrieved July 27, 2021.
  21. ↑ Comstock, Jonah (February 14, 2019). "AliveCor's new interim CEO talks debt funding, remote patient monitoring, other big plans for 2019". Mobile Health News. Retrieved July 27, 2021.
  22. ↑ Hendrickson, Zachary. "AliveCor drops Kardiaband Apple Watch Accessory – but it isn't losing much". Business Insider . Retrieved July 27, 2021.
  23. ↑ Farr, Christina (July 24, 2019). "Health-tech start-up AliveCor poaches an Amazon director to be its new CEO". CNBC. Retrieved July 27, 2021.
  24. ↑ Stempel, Jonathan (May 26, 2021). "Lawsuit claims Apple monopolizes heart-rate technology for Apple Watch". Reuters. Retrieved July 18, 2023.
  25. ↑ Song, Victoria (April 21, 2021). "A Health Tech Company Says the Apple Watch Is Infringing on Its ECG Patents". Gizmodo. Retrieved July 18, 2023.
  26. ↑ Brittain, Blake (December 5, 2022). "Apple sues AliveCor over patents as Apple Watch import ban deadline looms". Reuters. Archived from the original on March 6, 2023. Retrieved August 2, 2023.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  27. ↑ Brittain, Blake (December 7, 2022). "Apple wins AliveCor smartwatch patent challenges ahead of import ban ruling". Reuters. Archived from the original on March 6, 2023. Retrieved August 2, 2023.
  28. ↑ Song, Victoria (December 20, 2022). "Certain Wearable Electronic Devices With ECG Functionality and Components Thereof; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance and Suspension of a Limited Exclusion Order and a Cease and Desist Order; Termination of the Investigation". Federal Register. Retrieved July 18, 2023.
  29. ↑ Brittain, Blake (December 23, 2022). "Apple Watches violate AliveCor patents but import ban on hold -U.S. ITC". Reuters. Retrieved July 18, 2023.
  30. ↑ Evers-Hillstrom, Karl (February 21, 2023). "Apple Watches violate AliveCor patents but import ban on hold -U.S. ITC". The Hill. Retrieved July 18, 2023.
  31. 1 2 "Judge: No antitrust scheme by Apple in heart rate monitor app market". Courthouse News Service. August 2, 2023. Retrieved August 2, 2023.
  32. ↑ Stempel, Jonathan (February 6, 2024). "Apple beats AliveCor lawsuit over heart-rate apps for Apple Watch". Reuters. Retrieved February 10, 2024.
  33. ↑ "Apple Watch: What to Know About the Legal Disputes". TIME. 2024-02-08. Retrieved 2024-02-10.
  34. 1 2 Singh, Madhavi; Rao, Ravi; Gupta, Smriti (November 1, 2020). "KardiaMobile for ECG Monitoring and Arrhythmia Diagnosis". American Family Physician. 102 (9): 563–564. ISSN   1532-0650. Archived from the original on December 7, 2022. Retrieved August 2, 2023.
  35. ↑ Comstock, Jonah (August 21, 2014). "AliveCor gets FDA clearance for atrial fibrillation algorithm". MobiHealthNews. Retrieved July 27, 2021.
  36. ↑ AliveCor (2021). "How does the Single Lead KardiaMobile model communicate with my mobile device?". AliveCor Support by ZenDesk. Retrieved 19 April 2024.
  37. ↑ Hale, Conor (July 12, 2021). "AliveCor scores QT prolongation clearance for its portable ECG to track dangerous drug side effects". Fierce Biotech. Retrieved July 18, 2023.
  38. ↑ "AliveCor rolls out credit card-sized ECG". MobiHealthNews. February 1, 2022. Archived from the original on January 6, 2023. Retrieved August 2, 2023.
  39. ↑ Hackett, Mallory (July 9, 2020). "AliveCor adds ECG subscription service to its product line". Mobile Health News. Retrieved July 18, 2023.
  40. ↑ Whooley, Sean (May 3, 2022). "AliveCor launches KardiaComplete heart health management platform". Mass Device. Retrieved July 18, 2023.
  41. ↑ Buhr, Sarah (March 16, 2017). "AliveCor unveils an AI stroke prevention platform, inks $30 million from Omron and the Mayo Clinic". Techcrunch. Retrieved July 18, 2023.
  42. ↑ Park, Andrea (February 1, 2022). "AliveCor's credit-card-sized ECG snags FDA clearance for 30-second arrhythmia detection". Fierce Biotech. Retrieved July 18, 2023.
  43. ↑ Riley, Duncan (March 16, 2017). "Electrocardiogram app startup AliveCor raises $30M in new funding - SiliconANGLE". SiliconANGLE. Archived from the original on June 18, 2018. Retrieved August 3, 2023.
  44. ↑ "AliveCor raises $65 million to detect heart problems with AI". VentureBeat. 2020-11-16. Retrieved 2021-08-04.
  45. ↑ Newmarker, Chris (August 16, 2022). "GE Healthcare leads AliveCor Series F funding for ECG tech". Mass Device. Retrieved July 18, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.